Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory...

Published on 26 Mar 2024 on WCMH Columbus

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential Accord...

Insider Monkey · via Yahoo Finance 4 Dec 2024

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed o...

Benzinga · via Yahoo Finance 12 Nov 2024

Syndax Pharmaceuticals Inc (SNDX) reports robust financials and strategic milestones, including F...

GuruFocus.com · via Yahoo Finance 6 Nov 2024

Overview of the Recent Trade On September 30, 2024, State Street Corp made a significant addition...

GuruFocus.com · via Yahoo Finance 18 Oct 2024

With a robust cash position and strategic preparations for upcoming drug launches, Syndax...

GuruFocus.com · via Yahoo Finance 9 Oct 2024

On Wednesday, the FDA approved Incyte Corporation (NASDAQ:INCY) and Syndax Pharmaceuticals Inc’s...

Benzinga · via Yahoo Finance 22 Aug 2024

We recently compiled a list of the 10 Best Small-Cap Healthcare Stocks To Buy Now. In this articl...

Insider Monkey · via Yahoo Finance 22 Aug 2024

Syndax Pharmaceuticals SNDX stock rose 7.6% on Mar 27 after it announced a day before that the FD...

Zacks via Yahoo Finance 28 Mar 2024

Dr. Gallagher, with more than two decades of experience in the pharmaceutical and biotechnology...

Investing.com 27 Mar 2024

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...

WCMH Columbus 26 Mar 2024